- $488.07m
- $320.48m
- $10.84m
GlycoMimetics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Glycomimetics Reports Financial Results For Fourth Quarter And Year-End 2022
GlycoMimetics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Glycomimetics Inc Maintains Account At Silicon Valley Bank Holding Cash Deposits Of About $2 Mln
GlycoMimetics Inc expected to post a loss of 17 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Analog Devices, Biogen, Synopsys
Brief: Glycomimetics Announces Continuation Of Phase 3 Study Of E-Selectin Antagonist Uproleselan
Brief: Glycomimetics Announces Clinical Data In Acute Myeloid Leukemia
GlycoMimetics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Glycomimetics Reports Highlights And Financial Results For Third Quarter 2022
GlycoMimetics Inc expected to post a loss of 26 cents a share - Earnings Preview
GlycoMimetics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. As Chief Medical Officer
Brief: Glycomimetics Reports Highlights And Financial Results For Second Quarter 2022
Brief: Glycomimetics Inc Received Notice From Nasdaq Stock Market That Co Is Not In Compliance With Nasdaq's Listing Rule 5450(A)(1)
GlycoMimetics Inc reports results for the quarter ended in March - Earnings Summary
Brief: GlycoMimetics Reports Highlights and Financial Results for Q1 2022
GlycoMimetics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Glycomimetics Inc Files For Mixed Shelf Of Upto $250 Mln